The U.S. and Britain addressed a key unresolved issue in their trade agreement on Monday when the Trump administration agreed ...

GlaxoSmithKline ( ($GB:GSK) ) has shared an announcement. GSK plc announced the grant of options over Ordinary Shares as part of its Share Save ...

Damien Conover: In the large cap pharmaceutical space there is one name that really stands out from a valuation perspective, and that's GlaxoSmithKline. A lot of the reason why we think the stock is ...

British drugmaker GlaxoSmithKline and prominent genetic testing company 23andMe have launched human clinical trials for a jointly developed cancer drug, according to Bloomberg. In 2018, ...

U.K.-based GlaxoSmithKline surpasses Wall Street's profit expectations in the second quarter, and more importantly provides three reasons why investors may be able to stop worrying about its near-term ...

GlaxoSmithKline’s long-acting HIV drug cabotegravir is already challenging market leaders as part of an approved treatment regimen. Now, the medicine is a step closer to being a potential preventative ...

It's been a very different year so far for two big pharma stocks: One's hot and one's not. Things are going great for GlaxoSmithKlineplc (NYSE: GSK) as its share price is up around 15% year to date.

GlaxoSmithKline's ($GSK) respiratory business, struggling in the face of Advair price cuts, could use the few billion dollars analysts predicted it could generate if ...

For many Big Pharma companies the worst of the patent cliff is over. Within the last couple of years we've witnessed true heavy-hitting drugs, such as cholesterol-lowering drug Lipitor and asthma ...

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important ...